 |
Case Report
Cryopreservation after long-term testosterone therapy in the trans-male patient
1 Resident, Pennsylvania Hospital, University of Pennsylvania Health System Department of Obstetrics and Gynecol, Philadelphia, Philadelphia, USA
2 Medical Director, Society Hill Reproductive Medicine, Pennsylvania, Philadelphia, USA
Address correspondence to:
Jenna Kahn
MD, 800 Spruce Street, 2 Pine East Building, Philadelphia, Pennsylvania, 19107,
USA
Message to Corresponding Author
Article ID: 100048Z08JK2019
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Kahn J, Kelly M. Cryopreservation after longterm testosterone therapy in the trans-male patient. J Case Rep Images Obstet Gynecol 2019;5:100048Z08JK2019.ABSTRACT
Introduction: In an era of a growing transgender population with earlier intervention of hormonal therapy, there is little scientific literature describing effects of prolonged exogenous administration of testosterone on fertility. It is now more important than ever to understand the reproductive health needs of transgender patients and the potential long term effects of hormone therapy on fertility. The following case report demonstrates the fertility preservation potential in a trans-male patient after eight years of testosterone therapy.
Case Report: The patient is a 25-year-old G0 female to male (FTM) trans-male seeking fertility preservation. He had been taking consistent testosterone therapy since adolescence, a total of eight years prior to presentation. His last menstrual period was shortly after his hormonal therapy commenced. The patient was instructed to stop his testosterone therapy. Onset of menses occurred six weeks later. He started combined Oral Contraceptive Pills (OCPs) for ovulation suppression for seven days. Controlled ovarian stimulation was then initiated with home injections of Follistim (Ravensburg, Germany) and Menopur (Parsippany, NJ) for 11 days. Ganarelix (Ravensburg, Germany) was started on day-9 of stimulation. On day-11, his estradiol (E2) was 1339 pg/mL, there were nine follicles >16 mm and 10 follicles
Conclusion: This case demonstrates that fertility is possible for the young trans-male patient, regardless of the number of years of prior testosterone therapy. Providers must develop gender-appropriate support to address reproductive goals of their transgender patients.
Keywords: Cryopreservation, Fertility preservation Transgender, Testosterone therapy, Trans-male
SUPPORTING INFORMATION
Author Contributions
Jenna Kahn - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Maureen Kelly - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2019 Jenna Kahn et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
